Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida. Address: 555 Heritage Drive, Jupiter, FL, United States, 33458